Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
September 18, 2008

Trillium Pockets $12M to Progress Lead Preclinical Candidate

  • Trillium Therapeutics received $12 million from existing investors to advance its lead candidate into clinical development. TTI-1612 is a recombinant growth factor under parallel development for the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis.

    TTI-1612 is scheduled to begin clinical testing by the end of 2008, and two additional trials are projected to commence in 2009, Trillium reports.

    Trillium has two other preclinical programs, a CD200-specific anticancer mAb and a CD200Fc fusion protein for autoimmune and inflammatory diseases. The company says that it will use some of the funds to bring these compounds into clinical evaluations as well.

    The participating investors are VenGrowth Private Equity Partners, BDC Capital, and Canadian Medical Discoveries Fund.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.